This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article may be written from a fan's point of view, rather than a neutral point of view. Please clean it up to conform to a higher standard of quality, and to make it neutral in tone. (June 2021) (Learn how and when to remove this template message) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (June 2021) (Learn how and when to remove this template message) .mw-parser-output .hidden-begin{box-sizing:border-box;width:100%;padding:5px;border:none;font-size:95%}.mw-parser-output .hidden-title{font-weight:bold;line-height:1.6;text-align:left}.mw-parser-output .hidden-content{text-align:left}@media all and (max-width:500px){.mw-parser-output .hidden-begin{width:auto!important;clear:none!important;float:none!important))You can help expand this article with text translated from the corresponding article in Chinese. Click [show] for important translation instructions. View a machine-translated version of the Chinese article. Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Consider adding a topic to this template: there are already 338 articles in the main category, and specifying|topic= will aid in categorization. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Chinese Wikipedia article at [[:zh:康弘药业]]; see its history for attribution. You should also add the template ((Translated|zh|康弘药业)) to the talk page. For more guidance, see Wikipedia:Translation. (Learn how and when to remove this template message)

Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a publicly traded pharmaceutical company based in the province of Sichuan, China.[1] It was founded in 1996 and researches, develops, manufactures, and distributes medicines[2] for ophthalmic, central nervous, digestive and endocrine systems.[1] The company is listed on the Shenzhen stock exchange with a market capitalization at around $6 billion.[3][4]

As of May 2021, the company had 18 drugs on the market including Lumitin (conbercept).[5] Additional products include Songling xuemaikang capsules, Keluoxin capsules, Xinluona (Mosapride Citrate), Bolexin (Venlafaxine hydrochloride capsules) and Bosiqing (Aripiprazole tablets), Yitaning (Dexzopiclone tablets), Shugan Jieyu (capsules), Danshu (capsules), and Yiqing (capsules).[2][6] Kanghong also currently has 13 subsidiaries in China, Israel, and the United States.[7]

History

In 2005, Kanghong started development of the drug conbercept, which is used to treat age-related macular degeneration (AMD).[1] In 2017, Kanghong acquired IOPtima, a subsidiary of BioLight Israeli Life Sciences Investment.[4] Kanghong also became a distributor of IOPtima’s products in China.[4]

In 2016, Kanghong received approval from the U.S. FDA to begin Phase III clinical trials of conbercept. In 2020, the company’s R&D investments were approximately 29% of its annual revenue,[8] and by 2020, the company held 238 patents and exclusive patents for 13 drugs out of their 18 products.[5]

As of December 2020, the company’s drugs in development are for treatment of various diseases and conditions including glioma, fundus disease tumors, diabetic macular edema (DME), and Type II diabetes.[9]

During the COVID-19 pandemic, Kanghong donated money, protective clothing, and other materials to medical institutions across China through the China Red Cross Foundation.[10][11]

References

  1. ^ a b c "China Focus: Innovation boosts development of China's private medical companies". www.xinhuanet.com. Archived from the original on 2018-12-17. Retrieved 2021-05-27.
  2. ^ a b "002773.SZ - Chengdu Kanghong Pharma Grp Co Ltd Profile | Reuters". www.reuters.comundefined. Archived from the original on 2021-05-25. Retrieved 2021-05-27.
  3. ^ Baumer, Lilach (2018-09-27). "Chengdu Kanghong Pharma Solidifies Ownership of Israeli Medical Device Company". CTECH - www.calcalistech.com. Retrieved 2021-05-27.
  4. ^ a b c "Chengdu Kanghong Pharma buys Israel's IOPtima for $56m". Globes. 2017-11-21. Retrieved 2021-05-27.
  5. ^ a b "康弘药业亮相中国品牌日 | 北晚新视觉". www.takefoto.cn. Retrieved 2021-06-16.
  6. ^ "康弘药业:能成为第二个恒瑞医药吗? | 风云独立研报". finance.ifeng.com. Retrieved 2021-06-16.
  7. ^ "成都康弘药业集团股份有限公司_药智新闻". news.yaozh.com. Retrieved 2021-05-27.
  8. ^ "康弘药业2020年研发投入同比增长21.26% 加快创新布局未来 _ 东方财富网". finance.eastmoney.com. Retrieved 2021-05-27.
  9. ^ "康弘药业迎难而上,开拓研发创新新版图". finance.ifeng.com. Retrieved 2021-05-27.
  10. ^ "康弘药业疫情大考中彰显责任与创新-新华网". www.xinhuanet.com. Archived from the original on April 17, 2020. Retrieved 2021-06-16.
  11. ^ "与"白衣战士""战"在一起 康弘药业又一批国际采购医用防护物资到位". 2020-03-09. Archived from the original on 2021-06-24.